{
  "docId": "019de072-b09f-7797-83e5-c925df87e1b3",
  "docSlug": "fb96dc8e32131cd826524e728a742819",
  "documentTitle": "Compass Therapeutics | Investor Presentation Deck | 36 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 25,
  "pageCount": 36,
  "prevPage": 24,
  "nextPage": 26,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-b09f-7797-83e5-c925df87e1b3/25",
  "deckHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3",
  "deckJsonHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3.json",
  "deckAnchorHref": "/decks/019de072-b09f-7797-83e5-c925df87e1b3#slide-25",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.95,
        "x": 0.028,
        "y": 0.37
      },
      "kind": "list",
      "text": "Phase 2 (Stage 1): CTX-009 in combination with paclitaxel in patients with BTC is ongoing",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "043b5db5-a0aa-4643-b41f-50b79f4486ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.028,
        "y": 0.088
      },
      "kind": "list",
      "text": "Phase 2 (Stage 2): Plan to initiate Stage 2 in the US in early Q3",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4ae704ac-4b7d-41b7-82ae-18b2883168a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.028,
        "y": 0.23
      },
      "kind": "list",
      "text": "Phase 1: 8 PRs in patients with advanced cancers both as a monotherapy and in combination with chemotherapy with an acceptable safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72bfdfdb-9610-444f-a4e9-4be9417794fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.6,
        "x": 0.06,
        "y": 0.045
      },
      "kind": "list",
      "text": "Interim update (data as of April 14, 2022)\n24 patients with BTC have been enrolled and dosed\nAs of 4/14; 10 PRs for a 42% ORR (10/24)\nResponses observed across all 4 BTC subtypes\nMedian time on study is ~6 months\nAdverse event profile similar to Phase 1 studies",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9bc4a07-c3db-4eb9-a598-124b1a7ca5df",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.028,
        "y": 0.125
      },
      "kind": "title",
      "text": "CTX-009 Update: Executive Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "616b4345-df58-4009-84a2-1e51ff9b000a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "6e42ee59-00ff-4be4-ab08-b328f67e3ddb",
      "evidence": "The slide is titled 'CTX-009 Update: Executive Summary' and contains a summary of key points.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 36,
      "from": 25,
      "beatId": "c3e7dd54-708c-4a71-a4db-a7911d1931ca",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 25-36 present CTX-009 as a solution, showcasing its potential and clinical trial results.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 36,
      "from": 25,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "30be28e7-9f6a-4af1-9294-56a42dafdcd7",
      "evidence": "Slides 25-36 present CTX-009 as a promising solution, highlighting its potential for a quick win and big bet.",
      "position": 1,
      "objective": "Can CTX-009 provide a quick win and a big bet for BTC treatment?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}